论文部分内容阅读
目的:观察参芪金复方联合PP方案化疗治疗晚期肺腺癌的临床疗效及安全性。方法:将40例晚期肺腺癌患者随机分为治疗组和对照组。治疗组20例用培美曲塞+顺铂(PP方案)化疗,同时口服参芪金复方;对照组20例仅用PP方案化疗。两组均以21d为1个周期,治疗2个周期。观察并比较两组患者近期疗效、生存质量评分改善及不良反应发生情况。结果:有效率(CR+PR)治疗组为30.0%,对照组为25.0%,组间比较差异无统计学意义(P>0.05);治疗组在提高卡式评分及减轻PP方案毒副反应方面优于对照组(P<0.05)。结论:参芪金复方用于肺腺癌化疗的辅助治疗,可改善患者的生存质量,减轻患者化疗的毒副反应。
Objective: To observe the clinical efficacy and safety of Shenqijin combined with PP regimen in the treatment of advanced lung adenocarcinoma. Methods: Forty patients with advanced lung adenocarcinoma were randomly divided into treatment group and control group. Twenty patients in the treatment group were treated with pemetrexed plus cisplatin (PP regimen) and orally with Shenqijin compound (n = 20). The control group (n = 20) received PP regimen only. Two groups were 21d for a cycle, treatment 2 cycles. To observe and compare the two groups of patients with short-term efficacy, quality of life scores improved and adverse reactions. Results: The effective rate (CR + PR) was 30.0% in the treatment group and 25.0% in the control group, with no significant difference between the two groups (P> 0.05). In the treatment group, Better than the control group (P <0.05). Conclusion: Shenqijin Compound is used in adjuvant chemotherapy for chemotherapy of lung adenocarcinoma, which can improve the quality of life of patients and reduce the side effects of chemotherapy.